Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: A reduction in the expression of the pan T-cell markers CD7 and CD62L supports an endogenous T-cell dyscrasia. Previously, clone availability for CD62L restricted its application to frozen tissue sections.
Materials And Methods: A nonavidin/biotin technique to examine CD3, CD62L, and CD7 in paraffin formalin-fixed tissue in non-neoplastic and neoplastic T-cell infiltrates.
Results: In the reactive group, CD62L manifested a 15 and 22% reduction in epidermal and dermal staining, respectively; there was a 42 and 31% reduction in epidermal and dermal CD7 staining. In lymphomatoid hypersensitivity, CD62L showed a 24 and 9% reduction in epidermal and dermal staining, respectively; CD7 staining demonstrated reduced staining by 70 and 66% in the epidermis and dermis. In the non-lymphomatous endogenous T-cell dyscrasia and lymphoma categories, an 80% diminution in CD62L and CD7 expression was seen.
Conclusions: CD62L can be successfully applied in formalin-fixed tissue and exhibits enhanced specificity compared to CD7 in the evaluation of cutaneous T-cell infiltrates. Both CD62L and CD7 in paraffin-embedded, formalin-fixed tissue are useful diagnostic adjuncts, especially in regard to the discrimination of lymphomatoid hypersensitivity reactions from true endogenous T-cell dyscrasia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.0303-6987.2005.00259.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HIV-1 bNAb Vaccinal Effect - An Underachieving Goal?
Curr HIV Res
August 2025
U.S. Mil-itary HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Reports of HIV-1-specific broadly neutralizing monoclonal antibodies (bNAbs) medi-ating a potential 'vaccinal effect' implicate passively transferred bNAbs in promoting endoge-nous anti-HIV-1 immune responses. To date, three clinical trials have reported either increased anti-HIV-1 neutralizing antibodies or T cell responses following bNAb administration to people living with HIV. Despite strong enthusiasm for this hypothesis, motivated in large part by its potential application to HIV-1 therapeutic strategies, the mechanism(s) underlying a vaccinal ef-fect remain unclear.
View Article and Find Full Text PDFAdoptive Cell Therapy (ACT) has achieved curative responses in hematological malignancies, yet its translation to solid tumors remains limited by manufacturing bottlenecks, systemic toxicities, and poor T-cell infiltration and persistence within the immunosuppressive tumor microenvironment (TME). Here, we report the development and mechanism of ACTIVATE (Adoptive Cell Therapy and Immunostimulatory Vehicle for Anti-Tumor Efficacy), which leverages an injectable hydrogel depot technology that forms a transient inflammatory niche for localized co-delivery of adoptive T cells and native cytokines. By tuning cytokine identity, ACTIVATE enables precise modulation of T-cell expansion, effector function, and interaction with endogenous immune networks.
View Article and Find Full Text PDFComprehensive Analysis of lncRNA/circRNAs-miRNA-mRNA Networks of Oral Lichen Planus.
J Inflamm Res
August 2025
Department of Stomatology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
Background: Oral lichen planus (OLP) is T cell-mediated inflammatory disease affecting the oral mucosa, and its molecular mechanism remains poorly understood.
Objective: This study aimed to screen for OLP-related hub genes and construct a network of competing endogenous RNAs (ceRNAs) to explore the crucial mechanisms involved in the disease.
Methods: Proteomic and transcriptomic sequencing were performed on oral mucosa collected from OLP patients and healthy participants, respectively.
Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells.
Blood
September 2025
University of Minnesota, Minneapolis, Minnesota, United States.
The significance of endogenous immune surveillance in acute lymphoblastic leukemia (ALL) remains controversial. Using clinical B-ALL samples and a novel mouse model, we show that neoantigen-specific CD4+ T-cells are induced to adopt type-1 regulatory (Tr1) function in the leukemia microenvironment. Tr1s then inhibit cytotoxic CD8+ T-cells, preventing effective leukemia clearance.
View Article and Find Full Text PDFMethotrexate-Associated Primary Cutaneous Epstein-Barr Virus-Positive Polymorphic B-Cell Lymphoproliferative Disorder With Metachronous T-Cell Clonally Related Angioimmunoblastic T-Cell Lymphoma: A Case Report and Review of the Literature.
Am J Dermatopathol
September 2025
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY.
Primary cutaneous Epstein-Barr virus (EBV)-positive polymorphic B-cell lymphoproliferative disorder (LPD) is a rare LPD associated with iatrogenic and endogenous immune dysregulation with the commonest risk factor being immunosuppressive therapy. We present a 55-year-old woman with rheumatoid arthritis, previously on methotrexate, who developed a waxing and waning papulonodular eruption on the chest and neck. Histopathology revealed a lymphohistiocytic infiltrate with atypical EBV+/CD30+ B cells, consistent with EBV+ polymorphic B-cell LPD.
View Article and Find Full Text PDF